The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2026 | Updated results of the Phase III PERSEUS trial evaluating dara-VRd in newly diagnosed myeloma
In this video, Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, The Netherlands, provides an update on the Phase III PERSEUS trial (NCT03710603), which demonstrated the superiority of quadruplet therapy with daratumumab combined with bortezomib, lenalidomide, and dexamethasone (dara-VRd) versus VRd for the treatment of newly diagnosed multiple myeloma (MM). Prof. Sonneveld discusses ongoing follow-up analyses evaluating long-term progression-free survival, circulating tumor cells (CTCs), and outcomes among high-risk patients who achieve measurable residual disease (MRD) negativity. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, the PERSEUS trial has been completed, recruitment is complete, and we are now following these patients for a longer time to see if we can really acknowledge that the quadruplet with dara-VRd is definitely better than the triplet without dara. And I think it looks like that in all the interim analyses that we have done. But the projected progression-free survival is quite long, between 12 and 17 years...
So, the PERSEUS trial has been completed, recruitment is complete, and we are now following these patients for a longer time to see if we can really acknowledge that the quadruplet with dara-VRd is definitely better than the triplet without dara. And I think it looks like that in all the interim analyses that we have done. But the projected progression-free survival is quite long, between 12 and 17 years. And we have to wait for some more follow-up before we know what the benefit of adding dara will be. But for sure, the quadruplet is better than the triplet. We can say that now already. Other analyses are being performed as well. For example, the role of circulating tumor cells, circulating plasma myeloma cells, which is significant and an independent prognostic factor. And also the new criteria for high-risk disease have been implemented and have been analyzed, and this will be published hopefully soon. And then we will also publish the projected progression-free survival as done by the NICE criteria with different statistical models. This has been presented a couple of times already at clinical meetings, but now we are going to submit this for publication. And more analysis will follow, especially on the subgroup of high-risk patients that achieve Minimal Residual Disease (MRD) negativity, what will be the long-term outcome of this group of patients compared to patients that do not achieve MRD negativity or patients treated in the VRd arm.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
